Drug Trial Radar · NCT05053880
A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme
Last checked: Nov 19, 2026Latest source record: Jun 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Sep 22, 2021
Primary completion
Oct 25, 2024
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Accendatech USA Inc.Industry
- Sponsor type
- Industry
- Collaborators
- C3 Research Associates; Avance Clinical Pty Ltd.
- First posted
- Sep 23, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The current design provides a window to analyze the impact of the ACT001+Pembrolizumab combination on the tumor microenvironment and disease outcomes.
Conditions
- Recurrent Glioblastoma Multiforme(GBM)
Interventions
ACT001Drug
Phase1b - Starting approximately 2 weeks prior to the scheduled surgery, patient will receive an assigned dose of ACT001 by mouth in combination with a single dose of 200 mg pembrolizumab via an intravenous (IV-through a tube in vain) infusion in the clinic. Then patient will self administer ACT001 capsules twice daily by mouth, at the dose to which patient is assigned, until the evening prior to scheduled surgery. Patient will then undergo surgery to remove all or part of tumor. This a standard 3+3 dose escalation.
ACT001 + PembrolizumabDrug
Phase 2a - Starting approximately 2 weeks prior to the scheduled surgery, patient will receive a single dose of 200 mg pembrolizumab via an intravenous (IV) infusion in the clinic (an IV infusion means the drug will be delivered through a tube in your vein). Patient will then self-administer ACT001 capsules twice daily by mouth, at the dose to which patient is assigned, until the evening prior to scheduled surgery. Patient then will undergo surgery to remove all or part of tumor.
Primary outcomes
What the sponsor says the trial is designed to measure.
- 1b-Incidence, type and severity of treatment-emergent AEs (TEAEs)Time frame: Approximately 7 months. Each cycle is 21 days; from start of first dose with investigational product until completion of the last study related procedure (including follow-up for safety assessments- 30days after last dose)
- 1b-Dose limiting toxicities (DLTs)Time frame: From first dose of study therapy until the end of the first post-surgery cycle (Cycle 1, Day 21).
- 1b-Mean changes in vital sign measurements-Heart RateTime frame: Approximately 8months/ patient. Each cycle is 21 days. Start at screening, Pre-surgical Treatment Period, Cycle 1 and each subsequent Cycle and 30 days after last dose
- 1b-Mean changes in vital sign measurements- supine blood pressureTime frame: Approximately 8months/ patient.Each cycle is 21 days. Start at screening, Pre-surgical Treatment Period, Cycle 1 and each subsequent Cycle and 30 days after last dose
- 1b-Mean changes in vital sign measurements- body temperatureTime frame: Approximately 8months/ patient. Each cycle is 21 days. Start at screening, Pre-surgical Treatment Period, Cycle 1 and each subsequent Cycle and 30 days after last dose
- 1b-Mean changes in vital sign measurements- respiratory rateTime frame: Approximately 8months/ patient. Each cycle is 21 days. Start at screening, Pre-surgical Treatment Period, Cycle 1 and each subsequent Cycle and 30 days after last dose
- 1b-Mean changes in electrocardiogram (ECG) parametersTime frame: approximately 8months/patient. Each cycle is 21 days. Start at screening, Pre-surgical Treatment Period, Cycle 1 and each subsequent Cycle and 30 days after last dose
- 1b-Mean changes in Karnofsky Performance Scale scoreTime frame: Approximately 8 months/patient. Each cycle is 21 days. Start at screening, Pre-surgical Treatment Period, Cycle 1 and each subsequent Cycle and 30 days after last dose
- 2a-Progression free survival (PFS) at 6 monthsTime frame: Six months after initiation of study therapy
Locations
1 site in 1 country. Site status is shown where the registry gives one.
UT MD Anderson Cancer Center, Dept of Neuro-Oncology
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.